Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: OrganiGram Holdings (OGI), Taysha Gene Therapies (TSHA) and BioRestorative Therapies (BRTX)

Tipranks - Tipranks - Fri Feb 20, 7:32AM CST

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on OrganiGram Holdings (OGI – Research Report), Taysha Gene Therapies (TSHA – Research Report) and BioRestorative Therapies (BRTX – Research Report) with bullish sentiments.

President's Day Sale - 70% Off

OrganiGram Holdings (OGI)

In a report released today, Kenric Tyghe from Canaccord Genuity maintained a Buy rating on OrganiGram Holdings, with a price target of C$4.00. The company’s shares closed last Wednesday at $1.38.

According to TipRanks.com, Tyghe is a 4-star analyst with an average return of 16.8% and a 51.8% success rate. Tyghe covers the Healthcare sector, focusing on stocks such as Aurora Cannabis, Cronos Group, and Tilray. ;'>

Currently, the analyst consensus on OrganiGram Holdings is a Strong Buy with an average price target of $2.65, which is a 96.3% upside from current levels. In a report issued on February 10, Alliance Global Partners also maintained a Buy rating on the stock with a C$4.00 price target.

See today’s best-performing stocks on TipRanks >>

Taysha Gene Therapies (TSHA)

In a report released yesterday, Kristen Kluska from Cantor Fitzgerald maintained a Buy rating on Taysha Gene Therapies, with a price target of $19.00. The company’s shares closed last Wednesday at $4.65.

According to TipRanks.com, Kluska is a 5-star analyst with an average return of 26.3% and a 48.5% success rate. Kluska covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Ultragenyx Pharmaceutical, and Mereo Biopharma Group Plc. ;'>

Taysha Gene Therapies has an analyst consensus of Strong Buy, with a price target consensus of $12.80.

BioRestorative Therapies (BRTX)

Maxim Group analyst Michael Okunewitch maintained a Buy rating on BioRestorative Therapies yesterday and set a price target of $1.00. The company’s shares closed last Wednesday at $0.27.

According to TipRanks.com, Okunewitch has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -4.0% and a 36.7% success rate. Okunewitch covers the Healthcare sector, focusing on stocks such as Radiopharm Theranostics Limited Sponsored ADR, Rani Therapeutics Holdings, and Chemomab Therapeutics. ;'>

BioRestorative Therapies has an analyst consensus of Moderate Buy, with a price target consensus of $1.00.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).